EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL)
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), C.U. Blank, Anders Ekbom(Karolinska Institutet), L. Alfaya, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Cristian Ciria, Inge Marie Svane(Copenhagen University Hospital), Christoph Höeller(Medical University of Vienna), Claus Garbe(University of Tübingen), Lars Bastholt(Odense University Hospital), Vibeke Krüse, James Larkin(Trinity College Dublin), Laurent Mortier, Bart Neyns(Universitair Ziekenhuis Brussel), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), J.F. Baurain, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Peter Möhr
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k